New oral GLP-1s are designed to protect peptides, the active ingredients in these medications, so they can survive the trip through your digestive tract
Furthermore, these medications contribute to improved metabolic health and may lower the risk of cardiovascular diseases
Working with a doctor helps prevent the serious safety risks that can occur when GLP-1 medications are obtained or used outside of a clinical setting
Nonetheless, the magnitude of weight reduction observed at higher doses is notable given that achieving substantial weight loss in individuals with type 2 diabetes has historically been more difficult than in those with obesity alone, partly due to the metabolic effects of the condition itself and certain antidiabetic medications
In these trials, significant weight loss was demonstrated with liraglutide 3.0 mg therapy, compared to placebo (8.0% in SCALE obesity and prediabetes, 6.0% in SCALE-diabetes)
Nicholls DG